Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs

Completed · Phase 3

Conditions studied: Lennox-Gastaut Syndrome

In brief

This study was designed to evaluate the cognitive effect, safety, and pharmacokinetics (PK) of rufinamide on Lennox-Gastaut Syndrome (LGS) inadequately controlled in pediatric participants already taking other anti-epileptic drugs.

Key facts

Study ID
NCT01405053
Run by
Eisai Inc.
People needed
37
Starts
2011-06-16
Expected to finish
2015-11-02
Last updated by the study team
2019-08-06

Who can join

Age: 1 and older, up to 3. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.